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Monitoring α-Synuclein Proteotoxicity in DrosophilaModels
Aron Szabo and George K. Tofaris
Abstract
Parkinson’s disease is the second most common neurodegenerative disease without cure. It is characterized
by α-synuclein accumulation and aggregation in dopaminergic and other types of neurons. Because
α-synuclein accumulation leads to a toxic gain of function, its ectopic expression in Drosophila has been a
useful in vivo model for testing modifiers of its toxicity. This chapter describes four assays: the rapid iterative
negative geotaxis, rough eye phenotype, quantification of dopaminergic neuronal loss, and measurements
of circadian effects.
Key words Drosophila, Behavior, In vivo models, Morphology analysis, Neurotoxicity
1 Introduction
Parkinson’s disease (PD) is the second most common neurodegen-
erative disorder, affecting 1% of people over the age of 60. Clini-
cally, it is characterized primarily by a movement disorder causing
resting tremor, bradykinesia, rigidity, postural instability, and
diverse non-motor symptoms including dementia, which in
community-based studies was reported in up to 80% of patients
with a long disease duration. This latter finding indicates that PD is
a diffuse neurodegenerative disorder. Similarly, detailed neuropath-
ological studies have shown that intraneuronal inclusions called
Lewy bodies, which are one of the cardinal histological features of
the disease, are detected in numerous cortical areas and often
correlate with the extent of cognitive decline [1]. Despite this
diffuse evolution, the presentation to health services is commonly
due to the loss of a critical number of dopaminergic neurons in the
substantia nigra, but in patients with diffuse Lewy bodies disease
dementia may be the presenting feature. α-Synuclein is also the
major component of glial cytoplasmic inclusions that define multi-
ple system atrophy (MSA), a movement disorder characterized by
cerebellar ataxia, parkinsonism, and autonomic dysfunction. In
MSA, unlike Lewy body disease, α-synuclein inclusions are found
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in glial cells. The identification of additional causative genes of
familial PD that clinically mimic sporadic disease such as LRRK2,
VPS35, Pink1, and Parkin has suggested new mechanisms of path-
ogenicity [2]. A major limitation in translating this basic under-
standing into therapies is the lack of animal models that faithfully
recapitulate the human condition. In this respect, the use of simple
model organisms to interrogate in vivo the function of genes
against biochemical and cellular readouts has facilitated the
mapping of disease-causing genes with a fly ortholog into pathways
(e.g., mitophagy and endosomal-lysosomal trafficking) and sug-
gested novel therapeutic strategies in PD.
Drosophila melanogaster is a tractable organism for modeling
epistatic interactions in the context of pathological phenotypes.
Some of the advantages of utilizing Drosophila for genetic studies
include its short life span of 45–60 days, relatively low cost, and
evolutionary conservation of most genes. About 75% of human
genes have a Drosophila ortholog [3]. The development of the
Gal4-UAS system [4] has transformed the tractability of this organ-
ism for gene interaction studies. This combines the yeast transcrip-
tional activator Gal4 with UAS (upstream activation sequence), an
enhancer to which Gal4 specifically binds to activate gene transcrip-
tion. By fusing Gal4 to a tissue-specific promoter, it is possible to
drive the expression or knockdown of genes of interest in specific
cell populations [5].
Drosophila melanogaster has been extensively used to model
pathogenic processes, including neurodegenerative diseases. It has
been especially informative in the elucidation of the function of the
recessive PD genes Pink1 and Parkin in mitochondrial homeosta-
sis. The earliest evidence that Pink1 and Parkin function in the same
pathway came from phenotypic observations in Pink1 and Parkin
knockout flies which both exhibited swollen mitochondria with
broken cristae, muscle dysfunction, dopaminergic neuron degener-
ation, and reproductive defects [6, 7]. Parkin overexpression could
rescue the Pink1 mutant phenotypes whereas Pink1 overexpression
did not rescue the Parkin mutant ones [7–9] suggesting a linear
cascade with Pink1 upstream of Parkin. This has been delineated
mechanistically in mammalian cells where Pink1 activation phos-
phorylates ubiquitin and Parkin, activating Parkin-mediated
ubiquitination and mitochondrial autophagy [10]. Additional
insights came from the study of the LRRK2 ortholog in flies,
which provided early in vivo evidence for a role of this kinase in
endosomal trafficking, lysosomal function [11, 12], and synaptic
autophagy [13].
Flies do not have the α-synuclein (SNCA) gene and therefore
are not a suitable system to investigate its function. However, in
sporadic PD, neurodegeneration is thought to arise from accumu-
lation and misfolding of α-synuclein into oligomeric fibrillar spe-
cies, which acquire a toxic gain of function, partly by impairing
membrane fusion events [14]. In this context, ectopic expression of
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α-synuclein in different tissues using cell-type-specific drivers has
been shown to recapitulate cardinal features of Parkinson’s pathol-
ogy: Feany and colleagues first expressed human α-synuclein in the
nervous system of flies using the elav/Gal4 system [15]. Transgenic
flies showed age-dependent, progressive degeneration of the dor-
somedial (PPM1/2) cluster of dopaminergic neurons. The neuro-
degeneration was associated with an age-dependent decline in the
climbing ability of transgenic flies using a negative geostatic assay.
In addition, transgenic flies were shown to have neuronal
α-synuclein-immunoreactive cytoplasmic aggregates, which exhib-
ited a fibrillar ultrastructure under electron microscopy. The fly eye
consists of 760 unit eyes, called ommatidia, which contain photo-
receptors and bristles. Transgenic expression of α-synuclein in the
fly eye using GMR/Gal4 causes an architectural distortion, known
as rough eye phenotype that is associated with retinal degeneration
with vacuolization [15]. The rough eye phenotype induced by
α-synuclein toxicity is reversed by specific modifiers that were also
shown to directly regulate α-synuclein degradation in mammalian
cells [16, 17]. The observation that modifiers such as the E3 ligase
NEDD4 are protective in fly as well as rat models of α-synuclein
proteotoxicity [17] supports the notion that simplified in vivo
assays in flies may be especially helpful in the study of proteostasis,
where key enzymes are conversed across species.
Sleep timing is partly governed by the circadian clock, which
can be readily assayed in Drosophilamodels [18]. Sleep disturbance
is well documented in Parkinson’s patients and there is emerging
evidence that circadian defects occur in PD [19]. Recently, circa-
dian defects were observed in fly models expressing α-synuclein
[20] suggesting that this may be another simple behavioral readout
for in vivo quantification of α-synuclein toxicity.
Here, we describe four assays of α-synuclein proteotoxicity in
Drosophila: (1) rapid iterative negative geotaxis (RING) as a read-
out of motor activity, (2) rough eye phenotype, (3) tyrosine
hydroxylase (TH) immunostaining of the adult brain to track the
loss of specific dopaminergic neuronal subpopulations, and
(4) measurement of locomotor activity in response to circadian
rhythms as a potentially non-motor defect.
2 Materials
The following Drosophila lines are required: UAS-α-synuclein wild-
type (8146) and A53T mutant (8148), available from the Bloo-
mington Drosophila Stock Center. Driver lines such as GMR-Gal4
for eye-specific expression, ddc-Gal4 or TH-Gal4 for expression in
the dopaminergic neurons, elav-Gal4 for pan-neuronal expression,
and triple mutant TP-α-synuclein flies [21] are available from a
number of laboratories. Transgenic flies expressing α-synuclein
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and either RNAi or cDNA construct for the modifier of interest can
be generated to assay its knockdown or overexpression against
α-synuclein toxicity. Flies are typically aged for 30 days post-
eclosion.
2.1 Equipment 1. Dissecting stereomicroscope.
2. Sylgard-coated Petri dishes for dissection.
3. Dumont No. 5 forceps.
4. Insect pins.
5. Microscope slides.
6. No. 1 and No. 2 coverslips.
7. Imaging fluorescent microscope.
8. Light- and temperature-controlled incubators.
9. DAM2 Drosophila Activity Monitor (TriKinetics).
10. Glass tubes and tube caps for the monitors (TriKinetics).
11. PSIU9 Power Supply Interface Unit (TriKinetics).
12. DC Power Supply (TriKinetics).
13. Data collection computer.
14. FaasX software for data analysis.
15. Digital camera and timer.
16. Custom-made RING apparatus (see Fig. 1) and 50 mL Falcon
tubes.
17. JEOL JSM 6390 or similar scanning electron microscope.
18. Denton DV-503 vacuum evaporator.
19. SEM stubs.
2.2 Reagents 1. Fly food—Recipes can be found at the Bloomington Drosoph-
ila Stock Center website (https://bdsc.indiana.edu/informa
tion/recipes/index.html).
2. Phosphate-buffered saline (PBS).
3. Triton X-100.
4. Schneider’s Drosophila medium.
5. 4% Paraformaldehyde solution (PFA) in PBS.
6. Normal goat serum (NGS).
7. Primary antibody: Monoclonal mouse anti-tyrosine hydroxy-
lase (TH) (Millipore, MAB318, 1:500).
8. Fluorescently labeled secondary antibody (e.g., Alexa
488-coupled goat anti-mouse IgG (1:1000)).
9. SlowFade Diamond mounting medium.
10. 100% ethanol.
11. Milli-Q-grade water.




Locomotor function can be assayed using the rapid iterative nega-
tive geotaxis (RING) protocol, which is an adaptation from
Gargano et al. [22].
1. Transfer 10–20 male flies in a clean vial without anesthetizing
them with CO2 as flies can take up to 24 h to fully recover from
anesthesia.
2. Use 5 vials per line in each experiment (total 50 flies per line)
and mark each vial with a line at the 6 cm height (see Note 1).
3. Allow 15–20 min for the flies to acclimate to the environment.
4. For simultaneous testing of multiple vials, transfer the vials into
a custom-made RING apparatus (Fig. 1).
Fig. 1 Schematic illustration of the custom-made equipment for RING. This is comprised of an open-faced box
with a removable lid that can be assembled in the laboratory to hold the geotaxis vials of choice in place. A
digital camera is placed approximately 30 cm in front of the RING apparatus containing flies. Gentle tapping of
the apparatus causes a startle-induced fall of the flies to the bottom of each vial. Images are taken at 4 s after
tapping and the percentage of flies above a predefined height (in our case 6 cm) is estimated
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5. Place a digital camera in front of the apparatus (approximately
30 cm) so that the lens is at mid-height of the vials, focus and
zoom the camera to capture the image of the whole vial, and set
a timer to 4.0 s.
6. Tap the apparatus three times sharply ensuring that the tapping
is hard enough for all the flies to startle and drop to the bottom
of each vial.
7. With the third tap simultaneously start the timer and take the
picture at 4 s. Repeat at least five times.
8. Quantify the percentage of flies above the 6 cm mark. In our
experience this is a more accurate measurement of the locomo-
tion defect in the α-synuclein model compared to the average
distance traveled.
9. Repeat the experiment from at least two independently derived
transgenic lines (see Note 2).
3.2 Rough Eye
Phenotype
Although the rough eye phenotype is visible by light microscopy,
for more accurate quantification of the effect of modifiers we used
scanning electron microscopy (see Notes 3–6).
1. Fix age-matched, male flies in 70% ethanol.
2. Dehydrate the flies in 100% ethanol. The flies are then critically
point dried and mounted on SEM stubs.
3. Sputter coat the samples with 15 nm gold nanoparticles using a
Denton DV-503 vacuum evaporator or similar equipment and
image on a JEOL JSM 6390 or similar scanning electron
microscope.
4. Unless a complete rescue is observed, quantitate the eye phe-
notype, by randomly selecting 20 flies per genotype. Score the
images blindly using objective features of severity. Examine the
eyes for abnormal bristle orientation, ommatidial fusion or
pitting, and disorganization of the ommatidial array.
5. Score the phenotype by giving one point if any of the above
features is present, 2 points if it affects more than 5% of the eye,
and 4 points if it affects more than 25% of the eye.
3.3 Quantification of




1. Obtain adult flies expressing UAS-α-synuclein A53T with ddc-
Gal4 or elav-Gal4 and age them together with the single-
transgene controls to 25 days post-eclosion.
2. Anesthetize flies under CO2, rinse them in 100% ethanol for
20 s, and place them in ice-cold PBS transferring as little
ethanol as possible (see Note 7).
3. Pin one fly submerged in ice-cold Schneider’s Drosophila
medium onto a Sylgard-coated dish with two insect pins.
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4. Incise between the eyes on the top of the head using the
forceps. Extend the opening and gently peel off the eyes one
followed by the other.
5. Remove other appendages such as the proboscis and clean the
brain from tracheae and floating membranes (see Note 8).
6. Place brains in 1 mL ice-cold PFA in a microcentrifuge tube
and incubate rocking for 1 h at 25 C (see Note 9).
7. Let the brains settle to the bottom of the tube, aspirate PFA,
and rinse quickly twice with PBS + 0.05% triton X-100 (PBST).
8. Wash thrice for 20 min nutating in 1 mL PBST at room
temperature (RT).
9. Block with 1 mL 5% NGS in PBST at RT.
10. Add anti-TH primary antibody at 1:500 in 5% NGS, and
incubate at 4 C for 48 h.
11. Wash as for point 8.
12. Add secondary antibody in 5% NGS, and incubate at 4 C for
48 h in the dark.
13. Wash as for point 8 in the dark.
14. Prepare a microscope slide by placing a drop of SlowFade
(40 μL) in the center and create a bridge by positioning broken
No. 2 coverslips on the sides of the drop.
15. With a pipette and a cutoff P200 tip, transfer the brains from
the tube into the drop of SlowFade.
16. Align the brains so that the posterior side faces upwards.
17. Cover them with a No. 1 coverslip and seal with nail polish.
18. Proceed to imaging on an epifluorescent or confocal fluores-
cent microscope.
19. Identify TH+ dopaminergic neurons of the PPM1/2 cluster as




1. Place anesthetized flies individually into glass tubes containing
5% sucrose and 2% Bacto agar designed for DAM2 monitors
and close them with a cotton plug (see Note 10).
2. Fill the 32 channels of DAM2 with tubes representing one
genotype.
3. Place the DAM2-s into the incubators and connect them to
Power Supply Interface Unit through the phone cables.
4. Entrain flies for 3 days to 12-h light (L):12-h dark (D) cycles
and then leave them in constant darkness (DD) for 10 days at a
constant temperature of 25 C.
5. Extract the locomotor activity data from the recordings only
for the DD period of the experiment using the DAMSystem3
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Data Acquisition Software and DAMFileScan. Use bins of
5 min.
6. Apply the FaasX software (MacIntosh only, http://neuro-psi.
cnrs.fr/spip.php?article298&lang¼en) to analyze locomotor
activity data. Actogram allows the visualization of activity
patterns throughout the days. Cycle_p calculates the exact
period length in DD. Follow the instructions in the
startup kit (see Note 11).
4 Notes
1. We did not observe any desensitization of the flies on the
geotaxis assay up to ten consecutive trials spaced 1 min apart.
2. It is critical not to reuse the testing vials because new flies placed
into used vials do not climb to the same extent as in fresh vials.
3. We found that the α-synuclein-induced eye damage is observed
more consistently when flies were crossed and larvae kept at
29 C. Because the Gal4/UAS system is heat sensitive we
observed that a more consistent phenotype at 29 C that
correlated with a higher level of α-synuclein expression.
Under these conditions the rough eye phenotype was detected
from day 1.
4. Expression of the A53T mutant α-synuclein consistently
caused a more severe phenotype than wild-type α-synuclein,
which can be mild depending on the driver. The mutant con-
struct is more suitable for screening assays.
Fig. 2 Localization of PPM 1/2 neurons in the adult Drosophila brain. Schematic
diagram of the adult fly brain (grey) viewed from the posterior side. The neuropil
structures of the mushroom body (blue) and the fan-shaped body (yellow) are
indicated as an aid for orientation. Cell bodies of the TH+ PPM 1/2 cluster are
shown in the dorsomedial region of the brain. Note that their relative position can
vary between brains
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5. Homozygous GMR-Gal4 in flies per se can cause a rough eye
phenotype and therefore it is important that the driver is
heterozygous.
6. We noticed that the level of expression of α-synuclein varies
between different heterozygous GMR-Gal4 lines. It is there-
fore necessary to test and identify the best line that achieves the
highest expression of α-synuclein at 29 C without toxicity
when the driver alone is present.
7. The ethanol wash before brain dissection is critical as too little
wash will not soften the cuticle while too much will affect the
efficiency of dissection by lysing the fat body.
8. Leaving tracheae on the brain will make it float, and thus
reduces evenness of staining later.
9. Conditions for fixation with PFA depend on the antibody used
for staining—Shorter times or fixation on ice can increase
success of staining.
10. Ideally, flies are raised and aged on a light-dark schedule for
circadian experiments to facilitate later synchronization to LD.
11. Besides circadian rhythms, sleep can also be analyzed in LD by
applying a bin length of 1 min instead of 5 min and using the
Matlab script insomniac (Lesley Ashmore, University of
Pennsylvania).
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